Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding

AL Morrow and I Creese

[3H]Prazosin and [3H]WB4101 [2-(2,6-dimethoxyphenoxyethyl)aminomethyl- 1,4 benzodioxane] have both been proposed to label alpha 1-adrenergic receptors in the rat central nervous system. As many discrepancies between the binding of these two ligands have arisen, we conducted these studies in order to reevaluate their binding characteristics and resolve the similarities and differences in the pharmacological characteristics of their respective binding sites. [3H]Prazosin binding is characterized by a monophasic saturation isotherm. Prazosin, indoramine, and dihydroergocryptine competitions with [3H]prazosin are steep and monophasic, and model best to a single binding site. In contrast, phentolamine and WB4101 competition curves are shallow in rat cortex, exhibiting Hill coefficients significantly less than 1.0, and model to two binding sites of approximately equal proportions. The higher and lower affinity components are defined as alpha 1A and alpha 1B, respectively. [3H]WB4101 also labels two binding sites in rat cortex and hippocampus with picomolar and nanomolar affinity, respectively. However, the nanomolar binding site is serotonergic and not adrenergic. The picomolar site (KD = 150 pm) has characteristics of an alpha 1-receptor binding site: prazosin, WB4101, and phentolamine affinities for this [3H]WB4101 binding site correlate with their affinities for the highest affinity component (alpha 1A) of [3H]prazosin binding. In addition, the Bmax of this [3H] WB4101-labeled site is equal to one-half of the total [3H]prazosin Bmax. Agonist competitions with [3H]prazosin binding are multiphasic with pseudo-Hill slopes less than 1.0 and with a rank order of affinity of epinephrine greater than norepinephrine greater than phenylephrine. When binding to the alpha 1A component is blocked by a 30 nM phentolamine mask, the same rank order of agonist affinities is preserved. Although the affinities of epinephrine and norepinephrine at the two subtypes are identical, phenylephrine is weaker at the alpha 1B site. The ratio of the potency of phentolamine versus prazosin is about 4 at the alpha 1A component but about 80 at the alpha 1B binding site. We discuss these data in relation to the reported potencies of these antagonists in blocking alpha 1-receptor-mediated responses which may correlate with our designation of alpha 1A or alpha 1B binding sites.

Volume 29, Issue 4, pp. 321-330, 04/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				Z. Huang, L.L. Wu, Y.Y. Zhang, Y. Gao, and G.Y. Yu Functional {alpha}1-Adrenoceptor Subtypes in Human Submandibular Glands. J. Dent. Res., March 1, 2006; 85(3): 251 - 256. [Abstract] [Full Text] [PDF]

				C. S. Bockman, M. R. Bruchas, W. Zeng, K. A. O'Connell, P. W. Abel, M. A. Scofield, and F. J. Dowd Submandibular Gland Acinar Cells Express Multiple {alpha}1-Adrenoceptor Subtypes J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 364 - 372. [Abstract] [Full Text] [PDF]

				Z. Chen, G. Rogge, C. Hague, D. Alewood, B. Colless, R. J. Lewis, and K. P. Minneman Subtype-selective Noncompetitive or Competitive Inhibition of Human {alpha}1-Adrenergic Receptors by {rho}-TIA J. Biol. Chem., August 20, 2004; 279(34): 35326 - 35333. [Abstract] [Full Text] [PDF]

				A. Mihalyi, E. Ducza, R. Gaspar, and G. Falkay Investigation of the role of the serotonergic activity of certain subtype-selective {alpha}1A antagonists in the relaxant effect on the pregnant rat uterus in vitro Mol. Hum. Reprod., August 1, 2003; 9(8): 475 - 480. [Abstract] [Full Text] [PDF]

				Y. P. R. Jarajapu, F. Johnston, C. Berry, A. Renwick, J. C. McGrath, A. MacDonald, and C. Hillier Functional Characterization of alpha 1-Adrenoceptor Subtypes in Human Subcutaneous Resistance Arteries J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 729 - 734. [Abstract] [Full Text] [PDF]

				S. Guimaraes and D. Moura Vascular Adrenoceptors: An Update Pharmacol. Rev., June 1, 2001; 53(2): 319 - 356. [Abstract] [Full Text] [PDF]

				S. A. Argyle and J. C. McGrath An alpha 1A/alpha 1L-Adrenoceptor Mediates Contraction of Canine Subcutaneous Resistance Arteries J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 627 - 633. [Abstract] [Full Text]

				Y.-Y. Zhang, K.-M. Xu, and C. Han alpha 1-Adrenoceptor Subtypes Mediating Inotropic Responses in Rat Heart J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 829 - 836. [Abstract] [Full Text]

				Y. Ruan, H. Kan, J.-H. Parmentier, S. Fatima, L. F. Allen, and K. U. Malik Alpha-1A Adrenergic Receptor Stimulation with Phenylephrine Promotes Arachidonic Acid Release by Activation of Phospholipase D in Rat-1 Fibroblasts: Inhibition by Protein Kinase A J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 576 - 585. [Abstract] [Full Text]

				A. Hirasawa, T. Sugawara, T. Awaji, K. Tsumaya, H. Ito, and G. Tsujimoto Subtype-Specific Differences in Subcellular Localization of alpha 1-Adrenoceptors: Chlorethylclonidine Preferentially Alkylates the Accessible Cell Surface alpha 1-Adrenoceptors Irrespective of the Subtype Mol. Pharmacol., November 1, 1997; 52(5): 764 - 770. [Abstract] [Full Text]

				J. W. Hubbard, S. T. Nordstrom, C. P. Smith, K. M. Brooks, L. Laws-Ricker, L. Zhou, and H. M. Vargas alpha -Adrenergic Activity and Cardiovascular Effects of Besipirdine HCl (HP 749) and Metabolite P7480 in Vitro and in the Conscious Rat and Dog J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 337 - 346. [Abstract] [Full Text]

				K. Hirai, K. Kato, T. Nakayama, H. Hayako, Y. Ishihara, G. Goto, and M. Miyamoto Neurochemical Effects of 3-[1-(Phenylmethyl)-4-Piperidinyl]-1-(2,3,4,5-Tetrahydro-1H-1-Benzazepin-8-yl)-1-Propanone Fumarate (TAK-147), a Novel Acetylcholinesterase Inhibitor, in Rats J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1261 - 1269. [Abstract] [Full Text]

				S.-M. Yu, S.-Y. Tsai, J.-H. Guh, F.-N. Ko, C.-M. Teng, and J. T. Ou Mechanism of Catecholamine-Induced Proliferation of Vascular Smooth Muscle Cells Circulation, August 1, 1996; 94(3): 547 - 554. [Abstract] [Full Text]

				R. M. Graham, D. M. Perez, J. Hwa, and M. T. Piascik {alpha}1-Adrenergic Receptor Subtypes : Molecular Structure, Function, and Signaling Circ. Res., May 1, 1996; 78(5): 737 - 749. [Full Text]

				D. Duan, B. Fermini, and S. Nattel {alpha}-Adrenergic Control of Volume-Regulated Cl- Currents in Rabbit Atrial Myocytes : Characterization of a Novel Ionic Regulatory Mechanism Circ. Res., August 1, 1995; 77(2): 379 - 393. [Abstract] [Full Text]

				A. Wise, T. W. Lee, D. J. MacEwan, and G. Milligan Degradation of G[IMAGE][IMAGE]/G[IMAGE][IMAGE] Is Accelerated by Agonist Occupancy of [IMAGE][IMAGE], [IMAGE][IMAGE], and [IMAGE][IMAGE] Adrenergic Receptors J. Biol. Chem., July 21, 1995; 270(29): 17196 - 17203. [Abstract] [Full Text] [PDF]

				M. I. Fonseca, D. C. Button, and R. D. Brown Agonist Regulation of [IMAGE][IMAGE]-Adrenergic Receptor Subcellular Distribution and Function J. Biol. Chem., April 14, 1995; 270(15): 8902 - 8909. [Abstract] [Full Text] [PDF]